GT201

BIOLOGICAL5 trials

Sponsors

Grit Biotechnology, RenJi Hospital, Gritbio Medicine, Inc.

Conditions

Advanced Solid TumorsAdvanced Solid Tumors CancerSolid Tumor

Early Phase 1

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

RenJi HospitalSolid Tumor

Start: 2023-02-01End: 2025-05-01Target: 24Updated: 2023-02-13

Phase 1

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors

TerminatedNCT05430360

Grit BiotechnologySolid Tumor

Start: 2022-01-04End: 2025-12-30Updated: 2026-04-27

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

TerminatedNCT05729399

Grit BiotechnologySolid Tumor

Start: 2022-09-14End: 2025-12-30Updated: 2026-04-27

Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors

RecruitingNCT06144671

Grit BiotechnologyAdvanced Solid Tumors

Start: 2025-11-01End: 2027-12-30Target: 78Updated: 2026-08-19

Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.

Not yet recruitingNCT07766317

Gritbio Medicine, Inc.Advanced Solid Tumors Cancer

Start: 2026-11-01End: 2032-06-01Target: 63Updated: 2026-08-14

Related Papers

Assessing the safety and efficacy of GT201: A first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.

Journal of Clinical Oncology2025-05-281 citations

Exploring the safety and efficacy of GT201 as a first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.

Journal of Clinical Oncology2024-06-013 citations

Harnessing the power of tumor-infiltrating lymphocytes: A first-in-human study of GT201 as monotherapy in advanced solid tumors.

Journal of Clinical Oncology2023-06-014 citations